Abstract

BackgroundTumoral calcinosis (TC) is a rare disease derived from uremic secondary hyperparathyroidism (SHPT). However, parathyroidectomy (PTX) seems to be ineffective at relieving TC in some patients. In this study, we investigated the relationship between PTX and TC shrinkage.MethodsWe retrospectively followed up nine TC patients who underwent PTX, dividing them into two groups: those with TC size reduced by > 80% were in the “effective group” (group A), and the rest in the “ineffective group” (group B).ResultsWe enrolled nine patients (7 men; mean age 38.6 ± 10.9 years) with SHPT-related TC. One patient with calciphylaxis was excluded due to sudden death. The efficiency of PTX in causing TC regression was 62.5% (5 patients in group A). Group A had a shorter overall duration of TC (6 [5.5, 6.0] vs. 9 [8.0, 10.0] months; P = 0.02) and higher serum levels of alkaline phosphatase (ALP; 408.0 [217.9, 1101.7] vs. 90.8 [71.0, 102.1] pg/ml; P = 0.03) and high-sensitivity C-reactive protein (hs-CRP; 82.7 [55.0, 112.4] vs. 3.1 [3.1, 4.5] mg/l; P = 0.02). Average calcium supplementation within 1 week of surgery was significantly greater in group A than in group B (96.8 [64.1, 105.3] vs. 20.1 [13.1, 32.7] g; P = 0.04). Patients in both the groups demonstrated similar serum phosphate levels before PTX, but these levels were higher in group B than in group A at follow-up times (3 months, P = 0.03; 6 months, P = 0.03).ConclusionsThe shorter duration of pre-existing TC and higher ALP levels before PTX, as well as lower serum phosphate levels after PTX, were correlated with effective SHPT-TC shrinkage.

Highlights

  • Tumoral calcinosis (TC) is a rare disease derived from uremic secondary hyperparathyroidism (SHPT)

  • Patients in both the groups demonstrated similar serum phosphate levels before PTX, but these levels were higher in group B than in group A at followup times (3 months, P = 0.03; 6 months, P = 0.03)

  • Patient population From August 2012 to December 2017, SHPT was diagnosed in 597 patients, and of these, we retrospectively identified nine SHPT patients with TC (SHPT-TC) patients (7 men; mean age 38.6 ± 10.9 years)

Read more

Summary

Introduction

Tumoral calcinosis (TC) is a rare disease derived from uremic secondary hyperparathyroidism (SHPT). We investigated the relationship between PTX and TC shrinkage. Tumoral calcinosis (TC) is an uncommon end-stage renal disease (ESRD)-related complication in bone and mineral metabolism, with calcium phosphate deposits occurring in soft tissues. These deposits predominantly form around large articular areas and cause intolerable pain and skin ulceration [1, 2]. The aim of this study was to investigate the relationship between PTX and TC shrinkage

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call